Shengnuo Bio released its 2026 interim report, with net profit attributable to the parent company at 135 million yuan, up 51.98% from the same period last year. Total operating revenue was 507 million yuan, up 50.27% year on year, marking four consecutive years of growth. Net cash inflow from operating activities was 87.23 million yuan, up 6.82% year on year. The company's latest asset-liability ratio was 44.80%, gross margin was 58.73%, ROE was 11.82%, and diluted earnings per share was 0.61 yuan.
Cheng Du Sheng Nuo Biotec Co. Ltd. ANet profit up 51.98% and revenue up 50.27% in interim report
